| Pharmaceutical Information |
| Drug Name |
Tazemetostat |
| Drug ID |
BADD_D02598 |
| Description |
Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.[L11476] Tazemetostat was first named in literature as EPZ-6438.[A190363]
Tazemetaostat was granted FDA approval on 23 January 2020.[L11476] |
| Indications and Usage |
Tazemetostat is indicated to treat adult and pediatric patients 16 years and older with metastatic or locally advanced epithelioid sarcoma that is not eligible for complete resection.[L11476] |
| Marketing Status |
approved; investigational |
| ATC Code |
L01XX72 |
| DrugBank ID |
DB12887
|
| KEGG ID |
D11444
|
| MeSH ID |
C000593333
|
| PubChem ID |
66558664
|
| TTD Drug ID |
D00EQL
|
| NDC Product Code |
72607-100 |
| UNII |
Q40W93WPE1
|
| Synonyms |
tazemetostat | N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide | EPZ-6438 monohydrochloride | tazemetostat dihydrobromide | (1,1'-biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-, hydrobromide (1:2) | tazemetostat hydrochloride | (1,1'-biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-, hydrochloride (1:1) | tazemetostat monohydrochloride | tazemetostat hydrobromide | N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide monohydrobromide | tazemetostat monohydrobromide | EPZ-6438 monohydrobromide | EPZ-6438 trihydrochloride | EZ-438 | EZ438 | EPZ-6438 dihydrobromide | E 7438 | E7438 | E-7438 hydrobromide | Tazverik | EPZ-6438 | tazemetostat trihydrochloride |
|
| Chemical Information |
| Molecular Formula |
C34H44N4O4 |
| CAS Registry Number |
1403254-99-8 |
| SMILES |
CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5 |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
